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Ciprofloxacin, a second generation broad spectrum fluoroquinolone, is active against
both Gram-positive and Gram-negative bacteria. Ciprofloxacin has a high oral
bioavailability and a large volume of distribution. It is used for the treatment of
a wide range of infections including urinary tract infections caused by susceptible
bacteria. However, the availability and use of substandard and spurious quality
of oral ciprofloxacin formulations in the developing countries has been thought to
have contributed toward increased risk of treatment failure and bacterial resistance.
Therefore, quality control and bioequivalence studies of the commercially available
oral ciprofloxacin formulations should be monitored. Appropriate actions should be
taken against offending manufacturers in order to prevent the sale of substandard and
spurious quality of ciprofloxacin formulations.
Keywords: antibiotic resistance, ciprofloxacin, quality assurance, substandard drug, spurious drug,
pharmacovigilence and drug monitoring, drug regulatory system, fluoroquinolones
INTRODUCTION
Antibiotics, from natural or synthetic sources, inhibit the growth of microorganisms or kill the
bacteria (Barbereau, 2006; Nayyar et al., 2015; Reis et al., 2016). It is now evident that falsified
and counterfeit medications can cause treatment failure and antibiotic resistance (World Health
Organisation, 2016). According to the European Commission, falsified or fake medications are
the ones that pass themselves off as real, authorized medications without being evaluated for
their quality, safety and efficacy (European Commission, 2016). Such medications may contain
substandard active ingredients, which are of low quality and/or have incorrect amount, either
too high or too low (Lee et al., 2017). Counterfeit medications are, terminologically different
from falsified medications. Counterfeit refers to medications that do not comply with regulation
on intellectual and industrial property rights, for example, unregistered medicines sourced from
parallel import (Fadlallah et al., 2016; European Medicines Agency, 2017). In developing countries
including India, Pakistan, Bangladesh, Ethiopia, Nigeria, Kenya, Uganda, and Nigeria the control
and monitoring of drug manufacturing, marketing, distribution, and consumption is not strictly
controlled resulting in the availability of falsified medications. According to World Health
Organisation, up to 10% of medications may be falsified worldwide. Of these, 50% are estimated
to be antimicrobial agents of which 78% are from Asian and African countries (World Health
Organisation, 2016). Among falsified antibiotics, 43% have no active ingredients, 24% are of bad
Frontiers in Pharmacology | www.frontiersin.org 1 August 2017 | Volume 8 | Article 546
fphar-08-00546 August 18, 2017 Time: 16:19 # 2
Sharma et al. Quality of Ciprofloxacin and Antibiotic Resistance
quality, 21% are with less quantity of an active ingredient,
and 7% are with wrong ingredients (Delepierre et al., 2012;
Kratochwill et al., 2015). It was also found that the falsified
antibiotics consisted of 50% of beta lactams, 12% quinolones,
11% macrolides, 7% cyclins, and 20% other antibiotics. India
is reported as the leading country with the highest number of
falsified antibiotics followed by Burma and Nigeria (Kelesidis and
Falagas, 2015). More than 60,000 pharmaceutical formulations
produced in India are not registered (Bhargava and Kalantri,
2013) and the availability of substandard antibiotics is increasing
worldwide. This review mainly focuses on the availability of
substandard formulations of generic ciprofloxacin, a type of
quinolone, and its impact on bacterial resistance and treatment
failure.
Quinolones
Quinolones are classified according to their generations (Drlica,
1999). Nalidixic acid, the first generation quinolone, is effective
against Gram-negative bacteria excluding Pseudomonas species
(von Rosenstiel and Adam, 1994). The structure of nalidixic acid
is shown in Figure 1A. After intravenous administration, it is
eliminated very rapidly and therefore sufficient systemic levels
required for antibacterial effect cannot be achieved. Its plasma
half-life is about one and half hour, and because of its rapid
renal elimination, its use for the treatment of systemic infections
was not possible (von Rosenstiel and Adam, 1994). However, it
acted as an ideal urinary antiseptic, and, therefore, was used for
the treatment of urinary tract infections. Emergence of bacterial
resistance and high incidence of neurological, dermatological
and gastrointestinal side effects eventually limited its use in
clinical practice. Norfloxacin, ciprofloxacin, ofloxacin, enoxacin,
and lomefloxacin are examples of second generation quinolones.
Third generation quinolones include moxifloxacin, levofloxacin,
gatifloxacin, and sparfloxacin. Trovafloxacin is an example of
fourth generation quinolone (Neu, 1989).
Quinolones exert the potent antibacterial effect by binding
to bacterial enzymes, DNA gyrase and topoisomerase IV. This
binding results in the formation of quinolone–enzyme–DNA
complex. Shortly after binding, the enzyme undergoes
conformational changes. The enzyme breaks the DNA and
the drug prevents religation of the broken DNA strands, thus
preventing DNA replication. Ultimately, this results in the
damage to bacterial DNA and thus cell death (Stefan et al.,
2016). Unlike first generation, second generation quinolones
are effective against Pseudomonas species, some Gram-positive
bacteria (including Staphylococcus aureus but not Streptococcus
pneumoniae) and some atypical pathogens. The antimicrobial
spectrum of third generation quinolones is similar to that of
second generation but they have extended Gram-positive and
atypical microorganisms. Fourth generation quinolones are as
effective as third generation quinolones against Gram-negative,
Gram-positive and atypical pathogens but have broad anaerobic
coverage (Symonds and Nix, 1992).
Quinolones have a good oral bioavailability (Drlica, 1999).
Unlike most classes of antibiotics, the bioavailability of oral
quinolones (except norfloxacin) is comparable to quinolones
administered intravenously (Just, 1993; von Rosenstiel and
Adam, 1994). Therefore, often dose adjustment is not necessary
while switching from intravenous to oral quinolones. The
extent of absorption of orally administered quinolones is
significantly decreased if co-administered with products
containing positively charged cations such as zinc, aluminum,
calcium, and magnesium. The positively charged cations form
insoluble drug-cation complexes in the gastrointestinal tract
(GIT). Quinolones have a large volume of distribution and
their distribution in urinary tract and respiratory tissues is of
important because they are effective against microorganisms
commonly responsible for urinary tract and respiratory tract
infections (Davis et al., 1996).
Physicochemical and Pharmacokinetics
Characteristic of Ciprofloxacin
Ciprofloxacin, a second generation quinolone, has a pH
dependent solubility (Jaman et al., 2015). It’s solubility is
maximum at pH below 5 and minimum near to the isoelectric
point (pH 7) (Torniainen et al., 1996; Oishi et al., 2011). Besides,
ciprofloxacin in zwitterionic form was found to be most sensitive
to photodegradation at slightly basic pH (Torniainen et al.,
1996). For example, at pH 8.6, the percentage of ciprofloxacin
photodegradation is reported to be 85%. On the other hand, the
percentage of ciprofloxacin photodegradation decreases to 15%
at pH 3.0 and pH 4.0 whereas the extent of photodegradation is
similar at pH 6.0 and pH 10.6.
Ciprofloxacin is structurally similar to nalidixic acid
(Figure 1B) (Davis et al., 1996). The sixth position controls
the mechanism of action and bacterial potency of quinolones.
Unlike nalidixic acid, ciprofloxacin contains the fluorine atom
at position number 6. Due to this single change, ciprofloxacin
is approximately 100 times more potent than nalidixic acid.
Positions 1 and 7 seven control the potency spectrum and
pharmacokinetics of quinolones. N-ethyl and methyl groups
present on the first and seventh position of nalidixic acid
are replaced with a six-membered ring and N-cyclopropane
respectively in ciprofloxacin resulting in ciprofloxacin’s extended
Gram-negative activity, higher potency, better tissue penetration,
greater bioavailability, and longer plasma half-life (Sanchez
et al., 1992; Tillotson, 1996). It is used for the treatment of
a wide range of infections, such as complicated urinary tract
infections, bone or joint infections, cystic fibrosis, prostatitis,
typhoid, shigellosis, chronic suppurative otitis media, and
epididymo-orchitis caused by susceptible bacteria. Common
adverse drug reactions of ciprofloxacin include nausea, vomiting,
diarrhea, and abdominal pain. Thrombophlebitis at intravenous
infusion site, phototoxicity, transient hearing impairment, and
crystalluria are some of the infrequent and rare reported adverse
drug reactions of ciprofloxacin (Davis et al., 1996).
Following oral administration, ciprofloxacin is rapidly
absorbed in the GIT by passive diffusion and reaches the peak
serum concentration within 2 h. The absorption rate is affected
by intestinal pH, with greater absorption in the duodenum
and proximal jejunum than in the distal small intestine
(Campoli-Richards et al., 1988; Davis et al., 1996). Ciprofloxacin
demonstrates a concentration-dependent permeability and
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FIGURE 1 | Chemical structures of nalidixic acid (A) and ciprofloxacin (B).
it is widely distributed in body tissues and fluids including
bile, prostatic tissues, gingival fluid, and lungs. Clearance
of ciprofloxacin is by both renal and non-renal pathways
(Micromedex, 2016). Approximately, two third of metabolites
are excreted in the urine and 15% in feces (Olivera et al., 2011).
BIOAVAILABILITY AND
BIOEQUIVALENCE OF INNOVATOR AND
GENERIC CIPROFLOXACIN
Generic equivalents of brand-name drugs (innovator drugs) have
been introduced in the global healthcare market to lower the cost
of medications (Kaushal et al., 2016). A generic drug product is
assumed to be bioequivalent to the brand-name drug product
(innovator drug serve as the reference) if there is no statistically
significant difference in the rate and extent of absorption of the
active ingredient when administered at similar dose (Turner,
2016). Comparative bioavailability studies need to be established
before generic drug formulations are commercially available to
consumers. This is to assure that the safety and efficacy of
generic drug formulations are comparable to the corresponding
innovator drugs (Oishi et al., 2011).
Several human studies comparing the bioequivalence of
generic ciprofloxacin formulations to brand-name formulations
have been reported before. The reported studies compared
various pharmacokinetic parameters, such as extent of absorption
[area under the curve (AUC)], maximum plasma concentration
(Cmax), time to reach Cmax (Tmax) and half-life, between generic
and respective reference formulations. At three different oral
doses (250, 500, or 750 mg), pharmacokinetic parameters
of generic formulations were equivalent to the reference
formulations. As expected, a high dose of ciprofloxacin (750 mg),
often used in severe and/or complicated infections, showed
higher Cmax than 500 and 250 mg dose of ciprofloxacin.
Tmax and half-live values after the administration of 750 and
250 mg varied from 1.38 to 0.69 h and 4 to 5 h, respectively
(Plaisance et al., 1987). The oral bioequivalence of several
ciprofloxacin formulations at different doses are presented
in Table 1 (Azad et al., 2007; Hassan et al., 2007; Khan
et al., 2009; Fahmy and Abu-Gharbieh, 2014). These studies
reported that the rate and extent of absorption of the tested
generic formulations are similar to those observed with
brand-name formulations and therefore these generic and
brand-name formulations could be used interchangeably
(Azad et al., 2007; Valizadeh et al., 2012). However, 100s
of ciprofloxacin generic formulations of ciprofloxacin are
widely available worldwide. For example, there are more
than 75 pharmaceutical companies in India that manufacture
generic ciprofloxacin. Therefore, studies comparing the
bioequivalence of such formulations to brand-name formulations
are warranted.
Bacterial Resistance to Ciprofloxacin
Fluoroquinolone resistance occurs quickly and is related to
molecular evolutionary biology and direct response toward
drug pressure (Redgrave et al., 2014; Fasugba et al., 2015).
The most common type of clinically significant resistance is
alterations in the quinolone enzymatic targets, which is caused
by specific mutation of gyrase and topoisomerase IV which in
turn weakens the interactions between quinolones and bacterial
enzymes (Aldred et al., 2014). Plasmid mediated resistance is
another mechanism by which bacteria can acquire resistance
to quinolones. It is proposed that bacteria acquire plasmid
genes that code for proteins responsible for protecting bacterial
enzymes, DNA gyrase and topoisomerase IV, from the effect
of quinolones (van Hoek et al., 2011; Jacoby et al., 2014).
Chromosome mediated resistance is developed due to under
expression of porins or ever expression of cellular eﬄux pumps
decreasing the cellular concentration of quinolones (Naeem et al.,
2016; Turner, 2016).
Ciprofloxacin has been shown to be active against isolates
of various Gram-positive and Gram-negative bacteria, both
in vitro and in vivo (Tamma et al., 2012). It is one of the
antibiotics used for respiratory, urinary tract, intestinal and
abdominal infections caused by various pathogens including
Escherichia coli, Haemophilus influenzae, other H. spp.,
Neisseria gonorrhoeae, N. meningitides, Moraxella catarrhalis,
Klebsiella pneumoniae, Legionella pneumophila, Moraxella
catarrhalis, Proteus mirabilis, and Pseudomonas aeruginosa,
methicillin-susceptible Staphylococcus aureus, Streptococcus
pneumoniae, Staphylococcus epidermidis, Enterococcus faecalis,
and Streptococcus pyogenes (Rodriguez et al., 2009, 2015;
Vesga et al., 2010; Agudelo and Vesga, 2012; Tamma et al.,
2012). Nonetheless, concerns in relation to the appropriate
use of fluoroquinolones and quality of their pharmaceutically
equivalent formulations have been raised after the reported
therapeutic failures of fluoroquinolones including ciprofloxacin
when used for the treatment of various infections (Bowen et al.,
2015; De Lappe et al., 2015; Kim et al., 2015). One of the main
reasons for the reported treatment failure is thought to be due to
increased bacterial resistance to fluoroquinolones (Jabeen et al.,
2015).
Bacterial resistance to ciprofloxacin has been reported in
the early 90s and is continuously rising ever since (Cahana
et al., 1995; Corti et al., 1995; Hakanen et al., 1999).
For example, a study presented prevalence of ciprofloxacin
among 480 isolates obtained from patients with urinary tract
infections. The resistance rate to ciprofloxacin was 15.0%. High
resistance to ciprofloxacin was detected among Acinetobacter
haemolyticus (28.6%), Staphylococcus saprophyticus (25.0%)
(El Astal, 2005). Relatively recent systematic review and meta-
analysis of observational studies concluded that the resistance
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TABLE 1 | Mean (range) pharmacokinetic parameters from a single dose of reference and test tablets of ciprofloxacin.
Name and Number of healthy AUC∞
strength volunteers Type (mg/L∗h) Cmax (mg/L) Half-life (h) Tmax (h) Reference
Ciproxin R© (Bayer
health care
pharmaceuticals);
250 mg
24 adults Reference
formulation
6.92 (6.18–8.49) 1.46 (141–1.50) 4.52 (3.79–5.52) 1.20 (1.0–1.50) Azad et al., 2007
Quinox R© (Eskayef
Bangladesh, Ltd.);
250 mg
Test formulation 6.67 (6.18–8.48) 1.49 (1.39–1.62) 4.33 (3.90–6.46) 1.00 (1.0–1.50)
Ciproxin R© (Bayer
Laboratory);
500 mg
18 adults Reference
formulation
11.95 (7.96–19.51) 2.16 (1.19–3.23) – 1.56 (1.0–2.5) Morera et al., 2001
Cinaflox R© (Stein
laboratory); 500 mg
Test formulation 11.15 (7.77–16.05) 1.99 (1.41–2.79) – 1.63 (1.0–2.5)
Ciprobay R© (Bayer
Vital GmbH and
Co., Germany);
750 mg
24 adults Reference
formulation
15.70 (8.92–24.55) 3.32 (1.91–5.18) 5.00 (3.88–6.43) 1.49 (0.75–4) Cuadrado et al., 2004
Brand not
disclosed
(Dr. August Wolff
GmbH and Co.,
Germany); 750 mg
Test formulation 15.31 (8.92–22.51) 3.50 (2.12–5.15) 5.06 (3.95–6.31) 1.38 (0.75–2.5)
rate of urinary E. coli to ciprofloxacin is increasing and the policy
on appropriate use of ciprofloxacin should be developed and
enforced especially in developing countries (Fasugba et al., 2015).
Also, a study conducted in Brazil reported a much higher than
expected rate of bacterial resistance to ciprofloxacin (Reis et al.,
2016). Ciprofloxacin resistance varies significantly from country
to country with the highest resistance reported in developing
countries (Fasugba et al., 2015). Due to an increase in resistance,
Infectious Diseases Society of America (IDSA) recommends to
limit the use of fluoroquinolones to infections, where other
antibiotics cannot be used due to reasons including associated
side effects or causative organisms are found to be resistance to
alternative antibiotics.
Potential Reasons for Increased
Bacterial Resistance to Ciprofloxacin
There could be a number of reasons behind the observed increase
in bacterial resistance to ciprofloxacin. One reason could be
the overuse or misuse of ciprofloxacin likely to be due to
wide spread availability of generic versions of ciprofloxacin.
Overuse or misuse of antibiotics is known to promote bacterial
resistance and is likely to limit the effectiveness of ciprofloxaxin.
After the introduction of generic ciprofloxacin in the market,
an increase in consumption of ciprofloxacin was observed.
A study in Denmark showed that total consumption of oral
ciprofloxacin increased significantly from 0.13 to 0.33 defined
daily dose/1000 inhabitant-days. At the same time, the rate of
ciprofloxacin resistance has increased by 200% (Jensen et al.,
2010). In another study, it was reported that the resistance
of isolated E. coli obtained from patients with UTI increased
proportionally with the use of quinolones (Fasugba et al., 2015).
Similarly, a wide spread use of ciprofloxacin was thought to
be responsible for a significant rise in ciprofloxacin resistance
over time (Fasugba et al., 2015). As the driving force for the
prevalence of antibiotic resistance is the extent of drug use, there
is a positive correlation between consumptions of quinolones
and antibiotic resistance (Jensen et al., 2010). In certain parts
of the densely populated developing countries such as Brazil,
Indonesia, Pakistan, India and China, there are hot spots for
emergence and spread of antibiotic resistance (Huynh et al.,
2015). It was speculated that South Asia is the reservoir for
the global spread of ciprofloxacin-resistant infections caused by
various types of bacteria including S. saprophyticus, P. aeruginosa,
K. pneumoniae, multidrug-resistant Salmonella enterica serotype
Typhi/Paratyphi, E. coli, and Shigella sonnei (Rabaa et al.,
2016). Mulder et al. (2016) reported that the use of two,
three, or more prescriptions of fluoroquinolones during a
single infection was associated with bacterial resistance to
ciprofloxacin. Moreover, in certain parts of Africa, Asia and
Middle East, the use of prescription drugs without medical
advice is reported to be 100, 58, and 39%, respectively. The
frequent use of prescription drugs in such communities has
contributed to increase bacterial resistance (Morgan et al.,
2011).
Another reason for the observed increase in bacterial
resistance to ciprofloxacin could be due to easy accessibility
to substandard and spurious formulations of ciprofloxacin.
Substandard and spurious generic versions of drugs are
therapeutically ineffective when used clinically (Agudelo
and Vesga, 2012). As a consequence, treatment fails and
this potentially enhances the selection of bacterial resistance
(Rodriguez et al., 2009). Weir et al. (2005) collected 130
ciprofloxacin eye drop samples sold in India and then
randomly selected 30 samples for the analysis of ciprofloxacin
concentration. The authors reported that in 20% samples,
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the concentration of ciprofloxacin was below the standard
recommended range. In addition, a number of formulations
had the concentration of ciprofloxacin sufficiently lower to have
negative impact on clinical outcome leading to increased risk
of bacterial resistance. Prazuck et al. (2002) collected three
generic oral formulations of ciprofloxacin manufactured in India.
The content of ciprofloxacin in two out of three formulations
varied by more than −20%. One collected formulation in fact
expired 11 months ago. This study highlighted the availability
of poor quality of ciprofloxacin formulations in India. Previous
studies have also shown that the production of substandard
drugs is common in Southeast Asia (Newton et al., 2001).
Bate et al. (2009) determined the quality of various antibiotics,
including ciprofloxacin, commercially available in two major
Indian cities; namely Chennai and Delhi. They collected
50 and 53 ciprofloxacin treatment packs from Delhi and
Chennai pharmacies respectively. The quality was determined
based on the content of ciprofloxacin and disintegration test.
Approximately, 10% and 6% of ciprofloxacin collected from
Delhi and Chennai, respectively failed either one or two quality
tests. There could be a number of reasons behind the availability
of substandard ciprofloxacin worldwide. However, one of the
common reasons could be the lack of regulatory policies in
relation to both appropriate manufacturing practice and quality
assurance procedures.
Way Forward
Currently, approaches to determine bioavailability and
bioequivalence of pharmaceutical products has been largely
standardized. In United States, the sale of generic drugs
is approved by Food and Drug Administration when they
meet all the regulatory requirements provided in the Code
of Federal Regulations (Kaushal et al., 2016). The regulatory
environment of the country of marketing is important to assure
the assessment of bioequivalence of drug products. WHO
has made tremendous progress in developing international
consensus for standardizing and harmonizing the regulatory
requirement, mainly for manufacturing control, safety and
efficacy of new drugs and assessing bioequivalence of generics.
The national, regional organization and regulatory authorities
of developing countries including Central Drugs Standard
Control Organization (CDSCO), South African Development
Community (SADC), and Association of South East Nations
(ASEAN) should strive to provide comprehensive regulatory
guidelines related to product quality testing and conduct of
bioequivalence studies (Midha and McKay, 2009). Different
resources, expertise and stringent regulation and enforcement
are required to ensure proper implementation to ensure generic
formulations are safe and effective (Sarker et al., 2016). Moreover,
post-marketing surveillance is also necessary as the use of higher
strength drug than the labeled value can result in toxic effects
due to overdose whereas taking substandard agents can result in
treatment failure. Similarly, strict monitoring of the production
of ciprofloxacin formulations by drug regulatory agencies as
well as post-marketing quality control studies are required to
prevent and identify the substandard and spurious brands of oral
ciprofloxacin in order to prevent the risk of treatment failure and
antibiotic resistance.
CONCLUSION
The substandard quality ciprofloxacin is potentially the driving
force for ciprofloxacin resistance. The availability and use
of substandard quality ciprofloxacin would jeorpadise the
clincial efficacy of this broad spectrum antibitoic. Drug quality
assurance and strict laws and regulations for manufacturing,
importation, distribution, and sale of ciprofloxacin are required
to prevent the availability and use of substandard ciprofloxacin
formulations, which in turn will minimize the risk of treatment
failure and antibiotic resistance. An international comprehensive
policy for addressing the resistance of ciprofloxacin and other
fluroquinonoles in general is much needed.
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